PERNIX THERAPEUTICS HLDGS IN's ticker is PTX and the CUSIP is 71426V108. A total of 105 filers reported holding PERNIX THERAPEUTICS HLDGS IN in Q3 2015. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $585,000 | -29.0% | 941,155 | -48.9% | 0.00% | – |
| Q2 2016 | $824,000 | -56.3% | 1,840,487 | +2.4% | 0.00% | – |
| Q1 2016 | $1,887,000 | -64.3% | 1,796,619 | +0.4% | 0.00% | – |
| Q4 2015 | $5,281,000 | -3.9% | 1,790,106 | +2.9% | 0.00% | – |
| Q3 2015 | $5,498,000 | +1.9% | 1,739,845 | +90.8% | 0.00% | – |
| Q2 2015 | $5,398,000 | -41.1% | 911,728 | +6.4% | 0.00% | -100.0% |
| Q1 2015 | $9,158,000 | +40.7% | 856,759 | +23.6% | 0.00% | – |
| Q4 2014 | $6,508,000 | +35.2% | 693,146 | +10.6% | 0.00% | – |
| Q3 2014 | $4,813,000 | +3.8% | 626,703 | +21.4% | 0.00% | – |
| Q2 2014 | $4,636,000 | +87.3% | 516,284 | +11.6% | 0.00% | – |
| Q1 2014 | $2,475,000 | +149.0% | 462,748 | +17.2% | 0.00% | – |
| Q4 2013 | $994,000 | -7.6% | 394,748 | +0.2% | 0.00% | – |
| Q3 2013 | $1,076,000 | +3.6% | 393,976 | +36.9% | 0.00% | – |
| Q2 2013 | $1,039,000 | – | 287,773 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 2,484,649 | $7,330,000 | 8.59% |
| Avoro Capital Advisors LLC | 5,144,916 | $15,178,000 | 5.23% |
| Broadfin Capital, LLC | 6,090,829 | $17,968,000 | 1.10% |
| Aisling Capital LLC | 2,010,000 | $5,930,000 | 1.02% |
| Healthcare Value Capital, LLC | 150,000 | $443,000 | 0.73% |
| ACUTA CAPITAL PARTNERS, LLC | 434,300 | $1,281,000 | 0.61% |
| WALL STREET ASSOCIATES | 696,300 | $2,054,000 | 0.58% |
| SEARLE & CO. | 172,500 | $500,000 | 0.48% |
| Elk Creek Partners, LLC | 2,253,667 | $6,648,000 | 0.47% |
| KOPP INVESTMENT ADVISORS LLC | 315,293 | $931,000 | 0.46% |